Huntingtons Disease Treatment Market – By Drugs (Tetrabenazine, Deutetrabenazine), Type (Branded, Generic), Distribution Channel (Hospital, Retail, Online Pharmacies, Retail Pharmacies) – Global Forecast (2024 – 2032)

Huntington’s Disease Treatment Market Size

Huntington’s Disease Treatment Market size in 2023 was valued at USD 457.5 million and is poised to grow at 20.8% CAGR from 2024 to 2032. The market is experiencing significant growth, driven by the increasing prevalence of the disease and advancements in medical research.

Improved diagnostic tools and greater awareness have led to more cases being identified, which, in turn, boosts the demand for effective treatments. Advancements in genetic testing allow for earlier and more accurate diagnoses, resulting in timely interventions. Additionally, the introduction of generic versions of essential drugs like tetrabenazine has made treatments more accessible and affordable, further expanding the market.
 

Furthermore, increased funding and investments from governments, private investors, and pharmaceutical companies support the discovery and development of new therapies, further boosting market growth. The global aging population, which is more susceptible to neurodegenerative diseases, is also expected to drive demand for Huntington’s disease (HD) treatments.
 

HD treatment involves managing symptoms, as there is no cure. HD is characterized by a combination of motor, cognitive, and psychiatric symptoms, including involuntary movements (chorea), coordination problems, cognitive decline, and emotional disturbances. Pharmacological treatments include drugs like tetrabenazine and deutetrabenazine for chorea, and antipsychotics like haloperidol and olanzapine for psychiatric symptoms.
 

Huntington’s Disease Treatment Market Trends

• Increased research and development activities are significantly driving the growth of the market.
   
• Research into the genetic and molecular mechanisms underlying Huntington’s disease has provided deeper insights into how the mutated huntingtin protein gene affects brain function. This enhanced understanding enables scientists to identify potential therapeutic targets and develop more precise treatments.
   
• Pharmaceutical companies are investing heavily in drug discovery and development to create new treatments for HD. This involves high-throughput screening of drug candidates, preclinical studies, and clinical trials.
   
• For instance, Tominersen, formerly known as IONIS-HTT and RG6042, developed by Ionis Pharmaceuticals, is an investigational antisense drug currently in Phase 2 trials. It aims to address the root cause of Huntington’s disease by decreasing the production of all forms of the huntingtin protein (HTT), including the mutated variant (mHTT).
   
• Thus, the increasing focus on developing drugs that can slow or halt disease progression, rather than merely alleviating symptoms, is driving innovation and growth in the market.
   

Huntington’s Disease Treatment Market Analysis

Based on drugs, the market is classified into tetrabenazine, deutetrabenazine and other drugs. The tetrabenazine segment dominated the market with 47.8% of market share in 2023.
 

• Tetrabenazine is well-established as an effective treatment for managing chorea, a major symptom of Huntington’s disease. Its ability to significantly reduce involuntary movements and improve motor function contributes to its widespread use.
   
• Additionally, its early regulatory approval and recognition as a specific treatment for HD has solidified its significant position in the market.
   
• Furthermore, its availability in both branded and generic forms, has also helped in maintaining its significant market share by providing cost-effective treatment options.
   

Based on type, the Huntington’s disease treatment market is segmented into branded and generic. The branded segment accounted for USD 258 million in 2023.
 

• The highest growth of branded segment in the Huntington’s disease (HD) treatment market can be attributed to its established efficacy and strong brand recognition.
   
• Additionally, branded medications benefit from comprehensive regulatory approval and endorsements in clinical guidelines, which reinforce their use as standard treatments. This official backing provides assurance of their safety and efficacy, contributing to their dominance in the market.
   
• Patient and physician loyalty to these established brands further solidifies their leading position, as familiarity and a proven track record make them a go-to option for managing Huntington’s disease.
   

Based on distribution channel, the Huntington’s disease treatment market is bifurcated into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment held highest market share and is expected to reach USD 1.1 billion by 2032.
 

• Hospital pharmacies are well-equipped to provide these specialized drugs, including managing high-cost and branded medications like tetrabenazine and deutetrabenazine.
   
• Additionally, hospital pharmacies are integral to multidisciplinary care teams that include neurologists, psychiatrists, and other specialists. Their role in coordinating with these professionals ensures comprehensive and tailored treatment for HD patients. Such aforementioned factors further enhance their significance in managing HD, driving their dominant market share.
   

North America Huntington’s disease treatment market in 2023 was valued at USD 183.9 million and is expected to grow lucratively at 20.7% CAGR.
 

• North America has a relatively high prevalence of Huntington’s disease, coupled with increased awareness and early diagnostic capabilities.
   
• Improved diagnostic tools and awareness campaigns have led to higher rates of diagnosis and subsequently greater demand for effective treatments. This growing patient population drives the market's substantial value and growth potential.
   

The U.S. Huntington’s disease treatment market accounted for USD 167.7 million in 2023 and is projected to reach USD 894.4 million by 2032.
 

• U.S. is a hub for pharmaceutical research and development, with significant investments in the development of new and improved therapies for HD. The country’s strong emphasis on R&D has led to the introduction of novel treatments and clinical trials, driving growth in the HD treatment market.
   
• The region boasts advanced healthcare infrastructure and well-established medical facilities for effective management of HD, which further supports market growth in the U.S.
   

China Huntington’s disease treatment market is anticipated to experience remarkable growth over the forecast period.
 

• As the population ages and awareness improves, more cases of HD are being diagnosed, which boosts demand for effective treatments. Concurrently, China is investing heavily in expanding and modernizing its healthcare infrastructure. This development includes the establishment of advanced medical facilities and specialized care centers, which enhances access to and quality of HD treatments, further supporting market growth.
   

India is expected to showcase significant growth in global Huntington’s disease treatment market.
 

• The Indian government is increasingly focused on improving healthcare access and supporting research for rare disease treatment, providing funding and subsidies that facilitate the development and availability of HD treatments.
   
• Additionally, India's expanding pharmaceutical industry, including both domestic and international companies, is actively involved in researching, developing, and producing new therapies for HD.
   
• This robust pharmaceutical activity, combined with government initiatives, enhances the availability and innovation of HD treatments, driving market growth in India.
   

Huntington’s Disease Treatment Market Share

The Huntington’s disease treatment industry is characterized by a dynamic competitive landscape, with significant market share held by key pharmaceutical companies that offer specialized therapies for symptom management. The collaborations between pharmaceutical firms, research institutions, and patient advocacy groups are driving advancements and expanding treatment options.
 

Huntington’s Disease Treatment Market Companies

Prominent players operating in the Huntington’s disease treatment industry include:

• Bausch Health Companies Inc.
• CHEPLAPHARM Arzneimittel GmbH
• Dr. Reddy’s Laboratories Ltd.
• H. Lundbeck A/S
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Neurocrine Biosciences, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Upsher-Smith Laboratories, LLC.
   

Huntington’s Disease Treatment Industry News:

• In August 2024, Neurocrine Biosciences, Inc. announced the U.S. Food and Drug Administration (FDA) approval of the INGREZZA (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD). This strategic approval has helped the company diversify its product portfolio and boost revenue.
   

The Huntington’s disease treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drugs

• Tetrabenazine
• Deutetrabenazine
• Other drugs

Market, By Type

• Branded
• Generic

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa